AM6545

Overview

AM6545 is a highly selective, brain-free (peripherally active) CB1 receptor antagonist ( K i =1.7 nM). AM6545 inhibits endocannabinoid signaling by competitively antagonizing CB1 receptors, inhibiting CB1-mediated appetite stimulation and inflammatory responses without affecting cAMP levels. AM6545 significantly reduces food intake and body weight in mice, while improving metabolic syndrome-related renal impairment (such as proteinuria, fibrosis) and insulin resistance. AM6545 can be used in the study of obesity and its complications.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Pain | Products > Disease Areas > Obesity | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Cannabinoid Receptor

Product Information

• Catalog No.: HY-110206
• CAS No.: 1245626-05-4
• Molecular Formula: C26H23Cl2N5O3S
• Molecular Weight: 556.46
• Purity: 99.32%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (4.49 mM); Clear solution
• Availability: In-stock

Source

Original product source